We grant Climb Bio(NASDAQ stock code：CLYM）the exclusive rights to develop, manufacture and commercialize MIL116, an anti-APRIL monoclonal antibody, in the territory outside of Greater China.

We entered into a collaboration agreement with Kyinno Bio to co-develop a novel GPRC5D/BCMA/CD3 T-cell engager, MBS314.

We have established a strategic partnership with Betta (300558.SZ) to jointly invest in Foster Bio, a CDMO service provider. For more information, you can visit Foster Bio's website: http://www.fosterbio.com/

We have licensed Everest Medicines (HKEX Stock Code: 1952.HK) the clinical development and commercialization rights of Bejescin® in the Asia-Pacific region, other than Mainland China and Japan.